Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Blueprint Medicines Corporation BPMC

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:BPMC)

Fundamentals Snapshot (NDAQ:BPMC)

Current News (NDAQ:BPMC)

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire September 6, 2022

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC

Newsfile September 3, 2022

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC

PR Newswire August 29, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Newsfile August 24, 2022

CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis

PR Newswire August 24, 2022

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Newsfile August 23, 2022

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Newsfile August 22, 2022

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Accesswire August 19, 2022

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Newsfile August 19, 2022

Bullboard Posts (NDAQ:BPMC)